Jun Furusawa1,2, Yasushi Yamada1, Norihito Soga2, Isao Kuromatsu1. 1. Department of Urology, Nagoya Central Hospital, Aichi Cancer Center Hospital, Nagoya, Japan. 2. Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan.
Abstract
INTRODUCTION: Photoselective vaporization of the prostate (PVP) does not provide prostate tissue for pathologic analysis. Here, we carried out early monitoring for prostate cancer by measuring prostate-specific antigen (PSA) levels and assessing clinicopathological features after PVP. MATERIALS AND METHODS: Patients (n = 800) who underwent PVP and were followed-up for more than 12 months were analyzed retrospectively. After PVP, PSA levels were measured at 3 and 12 months and each year thereafter. Prostate biopsies were performed when PSA levels increased continuously. We assessed the characteristics of patients diagnosed with prostate cancer. RESULTS: The mean follow-up period was 49 months. After PVP, 54 patients underwent biopsies, and 23 patients were diagnosed with prostate cancer. Overall, 10, 10, and 3 patients had clinical stage T1c, T2a, and T2b disease, respectively, and there were no cases of stage T2c disease or greater. CONCLUSIONS: We found that it was possible to diagnose prostate cancer at a localized stage under our optimal PSA monitoring schedule before and after PVP.
INTRODUCTION: Photoselective vaporization of the prostate (PVP) does not provide prostate tissue for pathologic analysis. Here, we carried out early monitoring for prostate cancer by measuring prostate-specific antigen (PSA) levels and assessing clinicopathological features after PVP. MATERIALS AND METHODS: Patients (n = 800) who underwent PVP and were followed-up for more than 12 months were analyzed retrospectively. After PVP, PSA levels were measured at 3 and 12 months and each year thereafter. Prostate biopsies were performed when PSA levels increased continuously. We assessed the characteristics of patients diagnosed with prostate cancer. RESULTS: The mean follow-up period was 49 months. After PVP, 54 patients underwent biopsies, and 23 patients were diagnosed with prostate cancer. Overall, 10, 10, and 3 patients had clinical stage T1c, T2a, and T2b disease, respectively, and there were no cases of stage T2c disease or greater. CONCLUSIONS: We found that it was possible to diagnose prostate cancer at a localized stage under our optimal PSA monitoring schedule before and after PVP.
Authors: Carlos Capitán; Cristina Blázquez; M Dolores Martin; Virginia Hernández; Enrique de la Peña; Carlos Llorente Journal: Eur Urol Date: 2011-06-01 Impact factor: 20.096
Authors: Brandon Otto; Christopher Barbieri; Richard Lee; Alexis E Te; Steven A Kaplan; Brian Robinson; Bilal Chughtai Journal: Adv Urol Date: 2014-04-29